Methods for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass

Cardiopulmonary by-pass (CBP) during cardiac surgery leads to deleterious systemic inflammatory response. In a prospective cohort of 46 patients older than 18 years and eligible for non-urgent cardiac surgery with CPB, measurement of sTREM-1 in the plasma was performed immediately after the onset of anesthesia (H0) and 2 and 24 hours after CBP. After CBP, sTREM-1 significantly increased at H2 and at H24 (p<0.001). Based on both baseline sTREM-1 levels and variations, 3 patterns of patients were identified. Profile 1 group with high baseline sTREM-1 levels as well as high increase, developed more severe organ failure after CBP with higher norepinephrine dose at H24, higher SOFA score and more frequently AKI at both H24 and H48. Finally, acute atrial fibrillation at H24 was more frequent in profile 1 when compared to profile 2/3. Profile 1 group had longer ICU and hospital length of stay (LOS). In conclusion, early sTREM-1 variations after cardiac surgery identified a group of patients at high risk for post-operative AKI and prolonged length of stay. Thus sTREM-1 represents a relevant biomarker and biotarget in cardiac surgery with CBP.

Keywords: Cardiopulmonary by-pass (CBP), sTrem-1, severe organ failure, prognosis
Patent Application number: European Procedure (Patents) (EPA) - 11 Oct. 2021 - 21 306 422.3
Inventors:
AIT-OUFELLA HafidCLAVIER Thomas
Publications:
Front Cardiovasc Med 2023 Jul 13 Vandestienne et al. Soluble TREM-1 plasma levels are associated with acute kidney injury acute atrial fibrillation and prolonged ICU stay after cardiac surgery- a proof-concept stud doi: 10.3389/fcvm.2023.1098914.

Reference:

BIO21316-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 11-10-2021
Rare disease: No
Second indication: No

You might also be interested in